知临集团 APM 深 沪
等待开盘 11-14 09:30:00 美东时间
0.70
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.70
- 总市值 570.06万
- 52周最高 44.70
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.00
- 委 比 0.00%
- 总股本 814.38万
- 历史最高 3328.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.60
- 每 手 1
- 风险率 1.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Niki BioSolutions Announces Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 Conference
Niki BioSolutions subsidiary DiamiR Biosciences will present a poster at the 19th CTAD conference in Boston on November 19, 2026. The presentation, titled "Development and Analytical Validation of APOE Genotyping with Dried Blood Spots on FTA cards," focuses on APOE genotype testing via a fingertip prick, validated in Niki's CLIA-certified lab and recently approved by the New York State Department of Health. The CTAD conference is a key event in ...
11-09 16:40
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
Niki BioSolutions subsidiary DiamiR Biosciences has signed an agreement with Charter Research to perform APOE genotyping for Alzheimer’s disease trials. APOE status is critical for determining eligibility, safety monitoring, and risk stratification in Alzheimer’s research. The collaboration leverages Niki’s CAP-accredited and CLEP-approved testing platform, enhancing Charter Research’s ability to meet modern clinical trial requirements. This part...
10-23 12:00
Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
Niki BioSolutions subsidiary DiamiR Biosciences will perform APOE genotyping on plasma samples from GAP's Bio-Hermes-002 study, adding genetic risk data to help improve Alzheimer's clinical trial design and enrollment. The study focuses on underrepresented communities and integrates blood-based and digital biomarkers with amyloid PET imaging. DiamiR's assay allows genotyping from existing plasma samples, enhancing research efficiency. The collabo...
10-14 12:00
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
Niki BioSolutions, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026. The company will host a webcast presentation at 12:00 p.m. ET on September 29, accessible via the conference website or a direct link. Management will also hold one-on-one meetings with investors. Niki BioSolutions focuses on addressing unmet medical needs and providing genomic and biomarker testing solutions. For more informati...
09-25 12:30
Aptorum Group GAAP EPS of -$1.60
Aptorum Group press release (NIKI): 1H GAAP EPS of -$1.60. For the six months ended June 30, 2026, and 2025, net loss attributable to Niki BioSolutions, Inc. (excluding net loss attributable to non-co...
08-22 05:10
Aptorum Merges With DiamiR, Forms Niki BioSolutions
The latest announcement is out from Aptorum Group ( ($APM) ). On July 20, 2026,...
07-20 20:47
Aptorum Group Announces 1-For-10 Reverse Stock Split, Effective July 20; Proposed Merger With DiamiR Biosciences Anticipated To Close Around July 20
Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ: APM) ("Aptorum Group" or "Aptorum" or "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that the closing of its merger with DiamiR Biosciences Co...
07-16 23:03
Aptorum Group Provides Update on DiamiR Biosciences Merger
Aptorum Group and DiamiR Biosciences have finalized their merger, with the new company, Niki BioSolutions, Inc., set to trade on Nasdaq under "NIKI." The merger is expected to close on July 20, 2026. Aptorum is implementing a 1-for-10 reverse share split to increase its stock price and maintain compliance with Nasdaq listing requirements. The new company will be headquartered in Delaware and will combine Aptorum's biopharmaceutical expertise with...
07-16 15:00
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference
Aptorum Group and DiamiR Biosciences announced their upcoming presentations at the Alzheimer’s Association International Conference (AAIC) 2026, showcasing DiamiR’s biomarker technologies. Alidad Mireskandari, DiamiR’s CEO, will present three abstracts focusing on plasma-based APOE genotyping, circulating microRNAs as biomarkers for Alzheimer’s progression, and an automated APOE genotyping method. The presentations highlight advancements in blood...
07-08 12:00
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers
Aptorum Group and DiamiR Biosciences have entered into a definitive agreement for a merger, with shareholders approving the transaction on June 9, 2026. The merger is expected to close before fiscal 2027, subject to customary closing conditions. Upon completion, DiamiR will become a wholly-owned subsidiary of Aptorum Group, and the combined company will be renamed Niki BioSolutions, Inc. The collaboration between DiamiR and AlzLabs aims to develo...
06-22 12:00
